MedTrace Logo

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

NCT05766839 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-03-13

No results posted yet for this study

Summary

A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.

Conditions

  • Hyperkalemia

Interventions

DRUG

Patiromer

Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split

Sponsors & Collaborators

  • Vifor Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Julian Platon, MD, PhD · Vifor Pharma, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-06
Primary Completion
2029-12-01
Completion
2030-12-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Finland
  • France
  • Greece
  • Israel
  • Italy
  • Norway
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05766839 on ClinicalTrials.gov